The authors did not directly measure ApoA-I levels in MS patients, however because of the known effects of simvastatin on cholesterol metabolism (Matthan et al., 2003), the data strongly suggest that HDL and Apo A-I levels were higher in simvastatin group, where cholesterol was reduced from 5.5 to 4.1 mmol/L and brain atrophy was reduced by 43% (Chataway et al., 2014). The gene discussed is APOA1; the disease is myeloid sarcoma.